Nxera Pharma News

Nxera Pharma: Nxera’s Partner Neurocrine Biosciences Initiates Phase 3 Registrational Program of NBI-1117568 as Potential Treatment for Adults with Schizophrenia

Apr 30 19:30 ET

Nxera Pharma: Announcement of the commencement of phase 3 trials of NBI-1117568 targeting adult schizophrenia patients by Neurocline, our partner

Apr 30 19:30 ET

Nxera Pharma: Correction of the Securities Registration Statement (Reference Method)

Apr 16 02:57 ET

Nxera Pharma: Corrected securities registration form (reference method)

Apr 16 02:55 ET

Nxera Pharma: Correction of the Securities Registration Statement (Reference Method)

Apr 16 02:53 ET

Nxera Pharma: Extraordinary Report

Apr 16 02:51 ET

Nxera Pharma: Notice of Issuance of New Shares Under RSU Plan and Determination of Pmt Amount and Other Matters of Issuance of New Shares Under Previous Years’ RSU

Apr 16 02:30 ET

Nxera Pharma: Notice regarding the issuance of new shares based on the ex post grant type share compensation (RSU) system and the determination of the issue price etc. of new stock issues based on the RSU system in previous years

Apr 16 02:30 ET

Nxera Pharma: Corporate Governance Report 2025/04/11

Apr 11 03:56 ET

Nxera Pharma: Notice regarding the new management system

Mar 26 05:00 ET

Nxera Pharma: Correction of the Securities Registration Statement (Reference Method)

Mar 26 03:42 ET

Nxera Pharma: Corrected securities registration form (reference method)

Mar 26 03:41 ET

Nxera Pharma: Corrected securities registration form (reference method)

Mar 26 03:40 ET

Nxera Pharma: Interim report.

Mar 26 03:38 ET

Nxera Pharma: Internal Control Report - 35th Term (2024/01/01 - 2024/12/31)

Mar 26 03:37 ET

Nxera Pharma: Confirmation

Mar 26 03:36 ET

Nxera Pharma: Financial Report - 35th Term (2024/01/01 - 2024/12/31)

Mar 26 03:35 ET

Nxera Pharma: Nxera Pharma’s Partner Tempero Bio Initiates Phase 2 Trial with TMP-301 for Alcohol Use Disorder

Mar 24 19:30 ET

Nxera Pharma: Our partner Tempero Bio has begun phase 2 testing of TMP-301 targeting alcoholism

Mar 24 19:30 ET

Nxera Pharma: Independent Officer Registration Form

Mar 5 05:00 ET